You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
國藥一致(000028.SZ):2024年度淨利潤預降52.48%-64.92%
格隆匯 01-17 22:32

格隆匯1月17日丨國藥一致(000028.SZ)公佈2024年度業績預吿,2024年歸屬於上市公司股東的淨利潤盈利5.61億元–7.60億元,比上年同期下降52.48%-64.92%;扣除非經常性損益後的淨利潤盈利4.97億元–6.96億元,比上年同期下降54.59%-67.58%;基本每股收益盈利1.01元/股–1.37元/股。

報吿期內,門診統籌等醫改政策因素深刻影響了終端消費者的行為,醫藥零售門店客流下降,公司銷售額及利潤下滑。同時受醫藥零售行業競爭加劇、醫藥電商線上分流影響,行業出現了普遍下行的趨勢。結合以上現狀,根據商譽減值測試初步測試結果,公司本次擬計提的商譽及無形資產(品牌使用權和銷售網絡)減值準備金額約87,600萬元至107,000萬元,預計將減少報吿期內歸屬於上市公司股東的淨利潤50,500萬元至61,800萬元。

本次擬計提的上述商譽及無形資產減值系公司與公司聘請的評估機構和審計機構進行預溝通後確認的初步測算結果,最終計提減值準備金額將由公司聘請的評估機構及審計機構進行評估和審計後確定。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account